12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
A change may be coming. The "N" word. Referring to women in pornographic terms. Ethnic slurs. This...
Read More >
Federal Agency Determined That Employee Was Discharged After Requesting Disability-Related Leave Thr...
Read More >
As the world faces up to the challenges posed by the spread of COVID-19, clients have started asking...
Read More >
Seyfarth Synopsis: As we reported here, the CBD (cannabidiol) craze is sweeping the nation. By 2022,...
Read More >
Only the most notable legislation is addressed in this blog as it would otherwise be entirely too lo...
Read More >
Governmental agencies have been issuing a variety of guidance in the past 24 months that have change...
Read More >